Press Release April 27, 2020

ROME Therapeutics Launches with $50 Million Series A

The Life Sciences team advised on the launch of ROME Therapeutics and its $50 million in Series A funding from GV, ARCH Venture Partners and Partners Innovation Fund. ROME was founded to discover and develop novel therapies for cancer and autoimmune diseases by leveraging new insights from the vast uncharted territory of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats. 

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology.

The Goodwin team was led by William Collins, Sarah SolomonMitchell Bloom, Gabriela Morales-Rivera, Joel Denis and Karin Yoo

For additional details on the launch, please read the press release.